Abstract: Preparing a leucocyte-free blood by introducing a leucocyte containing liquid into a leucocyte removal filter; removing a first fraction from an effluent that is discharged from the leucocyte removal filter; obtaining an effluent portion that is discharged after the first fraction as a leucocyte-free blood preparation. A blood administration set including a leucocyte removal filter having an inlet port for introducing a leucocyte containing liquid, for separating leucocytes from the leucocyte containing liquid; and a passage for discharging a leucocyte-free blood preparation from the leucocyte removal filter. The passage has a device for removing a first fraction from an effluent discharged from the leucocyte removal filter. The method and blood administration set can avoid side effects that would otherwise occur when transfusion is performed using a leucocyte removal filter so that it is highly safe and that is simple and easy.

Abstract: An apparatus which can solve the problem of participation of NO in hypotension in dialysis, hypoxia in dialysis, and the like during artificial dialysis by continuously monitoring fluctuation in a blood gas, an ionic component, or the like in body fluid such as blood and by suppressing these diseases, and quality evaluating means of an artificial dialyzer and dialyzing fluid are provided. An apparatus for an artificial kidney comprises a measurement monitor for continuously measuring nitric oxide as a component of body fluid or liquid for treatment. Further, an apparatus for an artificial kidney comprises a measurement monitor for measuring a component of body fluid or liquid for treatment, a display means for comparing a measurement measured by the measurement monitor with a control value, and when the measurement equals the control value, displays the equality, and oxygen supplying means.

Abstract: A method for preparing a leucocyte-free blood preparation comprises the steps of: introducing a leucocyte containing liquid into a leucocyte removal filter; removing a first fraction from an effluent that is discharged from the leucocyte removal filter; obtaining an effluent portion that is discharged after the first fraction as a leucocyte-free blood preparation. A blood administration set comprising: a leucocyte removal filter having an inlet port for introducing a leucocyte containing liquid, for separating leucocytes from the leucocyte containing liquid; and a passage for discharging a leucocyte-free blood preparation from the leucocyte removal filter; wherein the passage comprises a device for removing a first fraction from an effluent discharged from the leucocyte removal filter. The method and blood administration set can avoid side effects that would otherwise occur when transfusion is performed using a leucocyte removal filter so that it is highly safe and that is simple and easy.

Abstract: An apparatus which can solve the problem of participation of NO in hypotension in dialysis, hypoxia in dialysis, and the like during artificial dialysis by continuously monitoring fluctuation in a blood gas, an ionic component, or the like in body fluid such as blood and by suppressing these diseases, and quality evaluating means of an artificial dialyzer and dialyzing fluid are provided. An apparatus for an artificial kidney comprises a measurement monitor for continuously measuring nitric oxide as a component of body fluid or liquid for treatment. Further, an apparatus for an artificial kidney comprises a measurement monitor for measuring a component of body fluid or liquid for treatment, a display means for comparing a measurement measured by the measurement monitor with a control value, and when the measurement equals the control value, displays the equality, and oxygen supplying means.

Abstract: New 1,4-dihydropyridine derivatives of the formula [I] are provided: ##STR1## wherein R.sup.1 represents a C.sub.1-4 alkyl group or a C.sub.3-6 alkoxyalkyl group, R.sup.2 represents a C.sub.1-8 alkyl group, and A represents an unsubstituted hexamethylene group or a substituted hexamethylene group having one or two C.sub.1-3 alkyl groups. The 1,4-dihydropyridine derivatives have vasodilating and hypotensive activity which is kept for a long period, and are useful in the treatment of cardiovascular disease and hypertention.

Abstract: Novel 1,4-dihydropyridine derivatives of the formula [I] are provided: ##STR1## wherein R.sup.1 represents a C.sub.1-4 alkyl group or a C.sub.3-6 alkoxyalkyl group, R.sup.2 represents hydrogen or halogen, R.sup.3 is either nitro when R.sup.2 is hydrogen, or halogen when R.sup.2 is halogen, R.sup.4 represents a pyridyl group, a phenethyl group, an unsubstituted benzyl group, a substituted benzyl group having one or more suitable substituents, an unsubstituted phenyl group, or a substituted phenyl group having one or more suitable substituents, and A represents an unsubstituted hexamethylene group or a substituted hexamethylene group having one or two C.sub.1-3 alkyl groups. The 1,4-dihydropyridine derivatives have vasodilating and hypotensive activity which is kept for a long period, and are useful in the treatment of cardiovascular disease and hypertension.